(101) METTL1 metilasaren eragina gaixotasun autoimmuneen garapenean

Laburpena

RNA eraldaketek gaixotasun autoimmuneen garapenean duten eragina geroz eta ikertuagoa da, baina oraindik patogenian duten inplikazioa ez dago guztiz argi. METTL1 entzimak katalizatutako m7G metilazioa hainbat gaixotasun autoimmuneekin lotu dira, baina honen eragina 1 motako diabetesean eta eritasun zeliakoan ez da oraindik ikertu. Ikerketa honetan METTL1ak bi gaixotasun hauen garapenean eta patogenian izan dezakeen eragina aztertu dugu. Orokorrean, gure emaitzek METTL1en desregulazioa azpimarratzen dute, METTL1 gainadierazita baitago eritasun zeliakoa pariatzen duten pazienteetan eta azpiadierazita infekzio birikoen edo hantura zitokinen eraginez zelula beta pankreatikoetan. The study of RNA modifications and their role in the development of autoimmune diseases has gained significant attention in recent years. However, their precise impact on disease pathogenesis remains largely unknown. Among these modifications, m⁷G methylation, catalyzed by the enzyme METTL1, has been implicated in various autoimmune diseases. Nonetheless, its specific effects on type 1 diabetes and celiac disease have yet to be fully elucidated. In this study, we investigate the role of METTL1 in the development and pathogenesis of these two autoimmune conditions. Our findings highlight the dysregulation of METTL1, which is upregulated in patients with celiac disease and downregulated in pancreatic beta cells exposed to inflammatory cytokines and viral infections.